Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Roxana S. Dronca MD Advisory Board

Lee S. Schwartzberg MD, FACP Advisory Board

Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor

See All Experts

featured

Published in Oncology

Expert Opinion / Interview · July 18, 2024

Perioperative Chemotherapy vs Neoadjuvant Chemoradiotherapy for Esophageal/GEJ Adenocarcinoma: ESOPEC

Interview with

Elizabeth Smyth MD

Interview with

Kai-Keen Shiu PhD, FRCP

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

story of the week

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

N. Engl. J. Med · December 26, 2024
featured

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

N. Engl. J. Med · December 25, 2024
featured

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

J. Natl. Cancer Inst · December 25, 2024
story of the week

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

N. Engl. J. Med · December 24, 2024
featured

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Blood · December 24, 2024
featured

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

N. Engl. J. Med · December 23, 2024
featured

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Lancet Oncol · December 19, 2024
story of the week

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

N. Engl. J. Med · December 18, 2024
featured

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Ann. Oncol · December 17, 2024
story of the week

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

Lancet · December 16, 2024
featured

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Clin. Cancer Res · December 13, 2024

updated

Perioperative Chemotherapy vs Neoadjuvant Chemoradiotherapy for Esophageal/GEJ Adenocarcinoma: ESOPEC

Further Reading

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Related Videos